PE20220217A1 - Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso - Google Patents

Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso

Info

Publication number
PE20220217A1
PE20220217A1 PE2021001081A PE2021001081A PE20220217A1 PE 20220217 A1 PE20220217 A1 PE 20220217A1 PE 2021001081 A PE2021001081 A PE 2021001081A PE 2021001081 A PE2021001081 A PE 2021001081A PE 20220217 A1 PE20220217 A1 PE 20220217A1
Authority
PE
Peru
Prior art keywords
family
chain region
beta chain
trbv9
methods
Prior art date
Application number
PE2021001081A
Other languages
English (en)
Spanish (es)
Inventor
Olga Vladimirovna Britanova
Dmitry Borisovich Staroverov
Anna Valentinovna Evstrateva
Alexey Konstantinovich Misorin
Timofey Aleksandrovich Nemankin
Mariia Aleksandrovna Shchemeleva
Anna Konstantinovna Vladimirova
Arina Vitalevna Anikina
Roman Alekseevich Ivanov
Dmitry Valentinovich Morozov
Pavel Andreevich Iakovlev
Sergey Anatolievich Lukyanov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of PE20220217A1 publication Critical patent/PE20220217A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2021001081A 2018-12-25 2020-02-20 Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso PE20220217A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018146031A RU2712251C1 (ru) 2018-12-25 2018-12-25 Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
PCT/RU2020/050024 WO2020139175A2 (ru) 2018-12-25 2020-02-20 Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения

Publications (1)

Publication Number Publication Date
PE20220217A1 true PE20220217A1 (es) 2022-02-02

Family

ID=69184123

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001081A PE20220217A1 (es) 2018-12-25 2020-02-20 Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso

Country Status (26)

Country Link
US (1) US12227572B2 (cg-RX-API-DMAC7.html)
EP (1) EP3907239A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022532274A (cg-RX-API-DMAC7.html)
KR (2) KR102788029B1 (cg-RX-API-DMAC7.html)
CN (2) CN113646333B (cg-RX-API-DMAC7.html)
AR (1) AR117734A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020204492B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012555A2 (cg-RX-API-DMAC7.html)
CA (2) CA3127767A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001705A1 (cg-RX-API-DMAC7.html)
CO (2) CO2021008218A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210354A (cg-RX-API-DMAC7.html)
EA (1) EA202191813A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21046333A (cg-RX-API-DMAC7.html)
IL (1) IL284370A (cg-RX-API-DMAC7.html)
JO (1) JOP20210169B1 (cg-RX-API-DMAC7.html)
MA (1) MA53689B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021007719A (cg-RX-API-DMAC7.html)
MY (1) MY205967A (cg-RX-API-DMAC7.html)
PE (1) PE20220217A1 (cg-RX-API-DMAC7.html)
PH (2) PH12021551775A1 (cg-RX-API-DMAC7.html)
RU (1) RU2712251C1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106975VA (cg-RX-API-DMAC7.html)
TW (1) TWI917314B (cg-RX-API-DMAC7.html)
WO (2) WO2020091635A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104357B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN116867519A (zh) * 2020-12-01 2023-10-10 约翰斯霍普金斯大学 治疗t细胞癌症的方法和材料
CN116510006A (zh) * 2022-01-31 2023-08-01 拜奥卡德联合股份公司 抗trbv9抗体的药物组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
CA2765949C (en) * 2009-06-25 2016-03-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения

Also Published As

Publication number Publication date
EP3907239A2 (en) 2021-11-10
KR102788029B1 (ko) 2025-03-31
CO2021009689A2 (es) 2021-08-09
CN113646333A (zh) 2021-11-12
EP3907239A4 (en) 2022-10-05
KR20210119404A (ko) 2021-10-05
IL284370A (en) 2021-08-31
JOP20210169A1 (ar) 2023-01-30
ZA202104357B (en) 2022-09-28
TWI917314B (zh) 2026-03-11
BR112021012555A2 (pt) 2021-09-14
WO2020139175A2 (ru) 2020-07-02
CN113646333B (zh) 2025-04-08
PH12021551775A1 (en) 2022-05-23
WO2020139175A3 (ru) 2020-10-29
EA202191813A1 (ru) 2021-10-07
WO2020091635A2 (ru) 2020-05-07
CO2021008218A2 (es) 2021-07-30
JP2022532274A (ja) 2022-07-14
CL2021001705A1 (es) 2022-01-28
JOP20210169B1 (ar) 2025-10-01
US20220112286A1 (en) 2022-04-14
CA3127767A1 (en) 2020-05-07
RU2712251C1 (ru) 2020-01-27
TW202039574A (zh) 2020-11-01
MA53689A1 (fr) 2022-06-30
MA53689B1 (fr) 2023-03-31
SG11202106975VA (en) 2021-07-29
CN114144432A (zh) 2022-03-04
US12227572B2 (en) 2025-02-18
MX2021007719A (es) 2022-03-25
AR117734A1 (es) 2021-08-25
ECSP21046333A (es) 2021-07-30
CA3124813A1 (en) 2020-07-02
WO2020091635A3 (ru) 2020-10-22
MY205967A (en) 2024-11-21
AU2020204492B2 (en) 2026-07-30
PH12021551532A1 (en) 2022-02-28
KR20220131489A (ko) 2022-09-28
CR20210354A (es) 2021-12-20
AU2020204492A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
EA202191939A1 (ru) Химерные антигенные рецепторы gprc5d и экспрессирующие их клетки
PE20200927A1 (es) Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PE20211217A1 (es) Anticuerpos estabilizadores de trem2
PE20211293A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
PE20220708A1 (es) Anticuerpos anti-cd73
PE20200384A1 (es) Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
EA202091228A1 (ru) Антитела, специфичные к иммуноглобулин-подобному транскрипту 3 (ilt3), и их применение
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
EA202191813A1 (ru) Моноклональные антитела против участка бета-цепи trbv9 человека
PE20211792A1 (es) Anticuerpos monoclonales que se unen especificamene a la region beta de la familia trbv-9 del receptor de celulas t humano, y los metodos para su uso
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
ES2658224T3 (es) Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos
PE20171107A1 (es) Anticuerpos mejorados contra il-6
PE20221273A1 (es) Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos
PE20191319A1 (es) Anticuerpos novedosos contra el factor xi y sus usos
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
AR115014A1 (es) Anticuerpos contra mica y/o micb y sus usos
EA201992335A1 (ru) Антитела против сортилина и способы их применения